FDA Determines Regulatory Review Period for INCIVEK Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of INCIVEK, a human drug product, in accordance with federal regulations and after receiving a patent extension application from the Department of Commerce.